← Back to Search

Monoclonal Antibodies

IPH5201 monotherapy dose escalation for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by MedImmune LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from time of informed consent through treatment period and including the follow-up period 12 weeks after last dose of investigational product, approximatley 7 months
Awards & highlights

Study Summary

This trial is testing a new cancer drug, IPH5201, to see if it is safe and effective when used alone or with other cancer drugs.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from time of informed consent through treatment period and including the follow-up 12 weeks after last dose of investigational product, approximately 7 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from time of informed consent through treatment period and including the follow-up 12 weeks after last dose of investigational product, approximately 7 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events as a measure of safety
Incidence of clinically significant electrocardiogram (ECG) abnormalities as a measure of safety
Incidence of clinically significant laboratory values as a measure of safety
Secondary outcome measures
Area under the curve (AUC) of IPH5201
DC (Disease Control; RECIST 1.1)
Half-life of IPH5201
+7 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: IPH5201 monotherapy dose escalationExperimental Treatment1 Intervention
IPH5201 monotherapy
Group II: IPH5201 dose escalation with durvalumab + oleclumabExperimental Treatment3 Interventions
IPH5201 plus durvalumab and oleclumab
Group III: IPH5201 dose escalation with durvalumabExperimental Treatment2 Interventions
IPH5201 plus durvalumab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IPH5201
2020
Completed Phase 1
~60
durvalumab
2017
Completed Phase 2
~400
oleclumab
2020
Completed Phase 1
~60

Find a Location

Who is running the clinical trial?

MedImmune LLCLead Sponsor
347 Previous Clinical Trials
793,852 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
2020. "IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04261075.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top